Novo Nordisk says the US FDA has approved a once daily pill version of Wegovy, described as the first approved pill of its kind The company said trials showed average weight loss of 16.6%, with about a third of roughly 1,300 participants losing 20% or more Novo Nordisk expects a US launch in early January 2026, with investors pushing shares up sharply after the announcement amid strong competition in the weight loss market US regulators have approved an oral version of Wegovy for chronic weight management, giving Novo Nordisk the first daily pill in this drug class cleared for obesity treatment, according to the company and US media reports
IVIM does not bill insurance directly and is a self-pay clinic, though it will run a prior authorization to check if your insurance company might reimburse you
Several cost-effectiveness studies project semaglutide 2.4 mg cost as producing $140,000-170,000/QALY increase at present list prices, more than conventional U.S
Nevertheless, preliminary estimates can be derived based on the studies currently available
As the bodily concentration of GHK-Cu declines with age, there is a consequential increase in inflammation, cancerous activity, and tissue destruction
Desbonnet et al., 2015)
